Intelligence / Healthtech / New Clinical Trials / Qilu Pharmaceutical Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
26 Oct 2026: Trial registered · QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 26 Oct 2026
- Title
- QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma
- Conditions
- Extrapulmonary Neuroendocrine Carcinoma
- Phase
- Phase 3
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07894211
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Qilu Pharmaceutical Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Qilu Pharmaceutical Co., Ltd. in our registers.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.